






A Gating strategy for 1 and 2 dpf for *drl:mCherry⁺;gata1:GFP⁺*




B Gating strategy 2 dpf for *runx1:mCherry⁺*




D Cell type identification of *drl:mCherry⁺;gata1:GFP⁺* using spliced RNA counts



F murine pre-HE gene set score





G murine HE/HSC gene set score




Supplemental Figure 1.

Figure S1, related to Figure 1. Supplemental scRNA-seq analysis. (A) Flow cytometry gating strategy for *drl:mCherry⁺ gata1:GFP⁻* cells to enrich for HSPCs at 1 and 2 dpf: 1) Forward scatter (FSC)-A vs side scatter (SSC)-A to exclude debris; 2) FSC-A vs FSC-W to select for single cells; 3) SSC-A vs SSC-W to select for single cells; 4) DAPI vs SSC-A to select for DAPI-negative viable cells; 5) mCherry-A vs SSC-A to select for *drl:mCherry⁺* cells; 6) GFP-A vs SSC-A to select for *gata1:GFP⁻* cells. (B) Flow cytometry gating strategy for *runx1:mCherry*-positive cells to enrich for HSPCs at 2 dpf using similar gating steps 1-4 as in (A). To select for *runx1:mCherry⁺* cells, GFP-A (autofluorescence) vs mCherry-A to select for *runx1:mCherry⁺* cells. Non-fluorescent wild-type controls were used to set gates for fluorescent protein expression (not shown). (C) UMAP dimensional reduction of *drl:mCherry⁺;gata1:GFP⁻* and *runx1:mCherry⁺* cells at 2 dpf. (D) Cell type re-identification for UMAP clustering in Figure 1D, S1E. Expression bars for heatmaps: scaling is performed per gene where mean is close to 0 and standard deviation of 1. (E) Monocle3 pseudotime trajectory overlaid over UMAP dimensional reduction of *drl:mCherry⁺; gata1:GFP⁻* cells at 1 and 2 dpf. Pre-HE identified as the start of pseudotime, or least differentiated, with EryP being at the end of the trajectory, or most differentiated cell state. (F-G) Left: Heatmap of gene-set scores for previously reported murine signature gene sets defining (F) pre-HE (Zhu, et al., 2020) and (G) HE//HSC (Hou, et al., 2020; Vink, et al., 2020; Zhu, et al., 2020; Zhou, et al., 2016). Right: Violin plots of gene set scores by cell type.





Supplemental Figure 2.

Figure S2, related to Figure 2. Supplemental *Switch* mCherry imaging analysis for Prog+ and HSC populations. (A) Fluorescent images of *Tg(drl:creER^{T2};ubi:Switch)* embryos for Prog+ (top panel) and HSC (bottom panel) mCherry-labeled populations at 3, 4, and 5 dpf. Yellow arrowhead indicates stationary HSPCs in the caudal hematopoietic tissue (CHT). Scale bar = 500 μ m. Representative images shown, quantification in B. (B) Quantification of mCherry⁺ CHT fluorescence from Prog+ and HSC lineage tracing cohorts. Mean \pm standard deviation of the *Switch* mCherry⁺ corrected total cell fluorescence (CTCF) at each time point is shown. Two-way ANOVA with Sidak's multiple comparison (N = 7-15 larvae/day). *p-value < 0.05, ****p-value \leq 0.0001.









Supplement Figure 3

Figure S3, related to Figure 3. Supplemental lymphoid lineage tracing quantification for Prog+ and HSC populations. (A) Quantification of mCherry⁺ thymic fluorescence from Prog+ and HSC lineage tracing cohorts. CTCF values for 4-OHT-treated embryos were normalized to ethanol controls. CTCF positive threshold of 7.5 (blue dotted line) was derived from a blinded analysis and demarcates the point at which mCherry⁺ fluorescence is visibly detected in the thymus. Two-way ANOVA with Sidak's multiple comparison was used for analysis. N = 6-30 per larvae/day. Plots are individual data points for each biological replicate with mean \pm standard deviation. *p-value < 0.05, ****p-value \leq 0.0001. (B) Quantification of the percentage of larvae with mCherry⁺ thymus based on fluorescence imaging and the threshold defined in S3A. (C) Receiving Operating Curve (ROC) was used to calculate a fluorescence threshold (7.5) demarcating the thymic mCherry⁺ fluorescence level for visual detection. Sensitivity and (1-Specificity) False Positive values were based on blinded scoring of 34 thymus images.



Supplemental Figure 4

Figure S4, related to Figure 4. Supplemental myeloid lineage tracing gating strategy for Prog+ and HSC populations. (A) Flow cytometry plots showing gating strategy for quantifying mCherry⁺ Prog+ and HSC lineage-traced cells. Live cells were selected based on lack of DAPI signal (A'), then single cells were selected using SSC-W vs SSC-H (A'') and FSC-W vs FSC-H (A'''). (B) Flow cytometry plots showing gating strategy for the *mpx:GFP^{high}* fraction and mCherry⁺ switch cells based on control groups. *mpx:GFP^{high}* negative controls: *Tg(drl:creERT²)*, *Tg(drl:creERT²;ubi:Switch)* with 4-OHT or EtOH; switch negative controls: *Tg(drl:creERT²; ubi:Switch)* and *Tg(drl:creERT²;mpx:GFP;ubi:Switch)* with EtOH; *mpx:GFP^{high}* positive controls: *Tg(mpx:GFP)* and *Tg(drl:creERT²;mpx:GFP;ubi:Switch)* with EtOH; and switch only positive controls: *Tg(drl:creERT²;ubi:Switch)* with 4-OHT.



Supplemental Figure 5.

Figure S5, related to Figure 5. Supplemental information for the establishment of *in situ* HSC regeneration assay using NTR/MTZ system in zebrafish. (A) Fluorescent images showing the expression of *drl:CFP-NTR* (A'), *drl:mCherry* (A''), and merged (A''') at 2 dpf. 1.75x inset in (A''') indicating co-expression in both circulating (white arrowheads) and stationary (yellow arrowheads) cells. Scale bar = 500 μ m. (B) Fluorescent images showing the expression pattern of *drl:CFP-NTR* within the CHT of 1–8 dpf zebrafish. Scale bar = 500 μ m. (C) Kaplan-Meier curve for the survival of embryos treated with 1% DMSO or 10 mM MTZ for 20 hours at 1 dpf and 2 dpf. (D) Kaplan-Meier curve for the development of edema in embryos treated with 1% DMSO or 10 mM MTZ for 20 hours at 1 dpf and 2 dpf. Graphs show survival/edema development of *drl:CFP-NTR* positive + 1% DMSO (purple), *drl:CFP-NTR* negative + 10 mM MTZ (light blue), and *drl:CFP-NTR* positive + 10 mM MTZ (red). Log-rank (Mantel-Cox) test used for statistical analysis at 1 and 2 dpf (N = 10-22 per treatment group, ****p-value \leq 0.0001). The solid lines are 1 dpf data and dotted lines are 2 dpf. (E) Fluorescent images of *Tg(drl:CFP-NTR;cd41:eGFP⁺)* and *Tg(cd41:GFP⁺)* embryos controls and experimental group at 2 and 4 dpf (0 and 2 dpM, respectively). Yellow arrowhead indicates stationary GFP⁺ CHT cells. Scale bar = 500 μ m. (F) Quantification of *cd41:GFP* fluorescence cell counts in *Tg(drl:CFP-NTR⁺;cd41:GFP⁺)* and *Tg(cd41:GFP⁺)* embryos treated with 10 mM MTZ or 1% DMSO (n = 3-15) from fluorescence images as shown in (E). Two-way ANOVA with Tukey's multiple comparisons test was used for all statistical analyses. Plots are individual data points for each biological replicate with mean \pm standard deviation. *p-value < 0.05, ***p-value \leq 0.001, ****p-value \leq 0.0001.